Vladimir Torchilin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11532450/publications.pdf

Version: 2024-02-01

25 papers 4,075 citations

430874 18 h-index 713466 21 g-index

26 all docs

26 docs citations

26 times ranked

6803 citing authors

#	Article	IF	CITATIONS
1	Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews, 2011, 63, 131-135.	13.7	1,741
2	Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 431-444.	4.3	524
3	Stimuli-sensitive nanopreparations for combination cancer therapy. Journal of Controlled Release, 2014, 190, 352-370.	9.9	299
4	Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharmaceutical Research, 1996, 13, 1378-1383.	3.5	174
5	Lipid-Core Micelles for Targeted Drug Delivery. Current Drug Delivery, 2005, 2, 319-327.	1.6	167
6	Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology. Journal of Controlled Release, 2008, 128, 255-260.	9.9	149
7	Antibody-modified liposomes for cancer chemotherapy. Expert Opinion on Drug Delivery, 2008, 5, 1003-1025.	5.0	135
8	Intracellulartransduction using cell-penetrating peptides. Molecular BioSystems, 2010, 6, 628-640.	2.9	118
9	Immunoconjugates and long circulating systems: Origins, current state of the art and future directions. Advanced Drug Delivery Reviews, 2013, 65, 24-35.	13.7	115
10	Polymeric Contrast Agents for Medical Imaging. Current Pharmaceutical Biotechnology, 2000, 1, 183-215.	1.6	114
11	Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 105, 40-49.	4.3	95
12	Converting Poorly Soluble Materials into Stable Aqueous Nanocolloids. Langmuir, 2011, 27, 1212-1217.	3.5	89
13	Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer. Drug Delivery, 2018, 25, 517-532.	5.7	84
14	Combined Radiofrequency Ablation and Adjuvant Liposomal Chemotherapy: Effect of Chemotherapeutic Agent, Nanoparticle Size, and Circulation Time. Journal of Vascular and Interventional Radiology, 2005, 16, 1365-1371.	0.5	80
15	Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: <i>In Vitro</i> Evaluation on HeLa, A2780-ADR, and H69-AR Cells. Molecular Pharmaceutics, 2016, 13, 428-437.	4.6	51
16	Quantum dot loaded immunomicelles for tumor imaging. BMC Medical Imaging, 2010, 10, 22.	2.7	34
17	siRNA Delivery by Stimuli-Sensitive Nanocarriers. Current Pharmaceutical Design, 2015, 21, 4566-4573.	1.9	26
18	Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro. Journal of Controlled Release, 2015, 220, 160-168.	9.9	22

#	Article	IF	Citations
19	Liposomes in Drug Delivery. , 2012, , 289-328.		17
20	Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. International Journal of Pharmaceutics, 2017, 532, 149-156.	5.2	15
21	Micellar formulations of pro-apoptotic DM-PIT-1 analogs and TRAILin vitroandin vivo. Drug Delivery, 2013, 20, 78-85.	5.7	13
22	Combination Nanopreparations of a Novel Proapoptotic Drug $\hat{a} \in \text{``NCL-240, TRAIL'}$ and siRNA. Pharmaceutical Research, 2016, 33, 1587-1601.	3.5	13
23	Raman Micro-Spectroscopy as a Non-Invasive Tool to Follow the Intracellular Fate of Nanoparticles. Frontiers in Nanobiomedical Research, 2014, , 489-510.	0.1	0
24	Stimuli-Sensitive Nanopreparations: Overview., 2016,, 1-48.		0
25	Tumor-specific Liposomal Nanomedicines., 2011,,.		O